Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cyclerion Therapeutics, Inc (CYCN) Fair Value & Analysis

Healthcare · US · Market cap $13.9M

Price$3.14
Fair Value$0.8600
Upside-72.6%
Quality95/100
Evidence: Low Range $0.5700 – $1.08

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cyclerion Therapeutics, Inc (CYCN) currently trades at $3.14, while our model-based Fair Value estimate is $0.8600 — implying the stock looks roughly 72.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Cyclerion Therapeutics, Inc (CYCN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.8600 versus a price of $3.14 — about −73% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CYCN?
Our 21-model fair value for Cyclerion Therapeutics, Inc is $0.8600 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.14.
What is the quality score of CYCN?
Cyclerion Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.